Johnson & Johnson presents new IMAAVY data while Johnson & Johnson stock trades EUR 227.50

Published on 10/04/2026 at 18:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock trades EUR 227.50 in weekend trading on October 4, 2026. New IMAAVY data were presented on September 29, 2026.

Isometric 3D illustration of a pharmaceutical campus with four color-coded sectors: a blue research lab with DNA helix, a grey manufacturing floor with conveyor belts, a teal medical devices room with surgical equipment, and a warm white consumer health s — Johnson Konzern isometrisch, US4781601046 mit Forschung Produktion Medical Devices und Consumer Health, Illustration mit AI erstellt.

On September 29, 2026, Johnson & Johnson presented new data on IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis, according to the company’s press release. At 6:06 p.m. CEST on October 4, 2026, Johnson & Johnson stock was at EUR 227.50 in weekend trading at Lang & Schwarz, unchanged at 0.00 percent versus the EUR 227.50 close at Lang & Schwarz on October 2, 2026.

Weekend trading

The Lang & Schwarz bid was EUR 227.25 and the ask was EUR 227.75 at 6:06 p.m. CEST on October 4, 2026. The price remained EUR 0.00 above or below the EUR 227.50 close at Lang & Schwarz on October 2, 2026. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CEST is shown by the continuously updated real-time quote of Johnson & Johnson stock.

IMAAVY data

Johnson & Johnson said the new two-year findings from a Phase 2/3 long-term extension showed sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in anti-AChR-positive adolescents. The company also reported that a retrospective survey in adults identified fluctuating symptom control as a leading reason for discontinuing prior advanced treatment. These details were included in the Johnson & Johnson release.